Unicycive Historical Income Statement

UNCY Stock

USD 0.69 0.01 1.47%

Historical analysis of Unicycive Therapeutics income statement accounts such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K, Depreciation And Amortization of 386.4 K or Selling General Administrative of 4.4 M can show how well Unicycive Therapeutics performed in making a profits. Evaluating Unicycive Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Unicycive Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Unicycive Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Unicycive Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

About Unicycive Income Statement Analysis

Unicycive Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Unicycive Therapeutics shareholders. The income statement also shows Unicycive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Unicycive Therapeutics Income Statement Chart

At this time, Unicycive Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 386.4 K in 2024, whereas Interest Expense is likely to drop slightly above 77.9 K in 2024.

Interest Expense Selling General Administrative Total Operating Expenses Cost Of Revenue

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Cost Of Revenue

Cost of Revenue is found on Unicycive Therapeutics income statement and represents the costs associated with goods and services Unicycive Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Unicycive Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 386.4 K in 2024, whereas Interest Expense is likely to drop slightly above 77.9 K in 2024.

Unicycive Therapeutics income statement Correlations

	Ebit	Net Interest Income	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Selling And Marketing Expenses
Ebit		-0.73	-0.15	-0.92	-0.91	0.98	1.0	-0.9	1.0	-0.91	1.0	0.9	1.0	0.03	-0.87	-0.9	0.83
Net Interest Income	-0.73		0.04	0.62	0.55	-0.65	-0.71	0.51	-0.75	0.55	-0.73	-0.8	-0.72	-0.59	0.68	0.84	-0.8
Depreciation And Amortization	-0.15	0.04		0.07	0.09	-0.11	-0.12	0.09	-0.12	0.09	-0.13	-0.14	-0.13	0.14	0.1	0.14	-0.14
Selling General Administrative	-0.92	0.62	0.07		0.99	-0.95	-0.93	0.98	-0.92	0.99	-0.92	-0.73	-0.92	-0.11	0.92	0.72	-0.57
Other Operating Expenses	-0.91	0.55	0.09	0.99		-0.96	-0.92	1.0	-0.91	1.0	-0.91	-0.68	-0.91	-0.05	0.93	0.68	-0.54
Operating Income	0.98	-0.65	-0.11	-0.95	-0.96		0.99	-0.96	0.98	-0.96	0.98	0.8	0.98	0.03	-0.93	-0.81	0.74
Net Income From Continuing Ops	1.0	-0.71	-0.12	-0.93	-0.92	0.99		-0.92	1.0	-0.92	1.0	0.89	1.0	0.02	-0.88	-0.89	0.82
Research Development	-0.9	0.51	0.09	0.98	1.0	-0.96	-0.92		-0.9	1.0	-0.9	-0.65	-0.9	-0.02	0.93	0.65	-0.52
Ebitda	1.0	-0.75	-0.12	-0.92	-0.91	0.98	1.0	-0.9		-0.91	1.0	0.9	1.0	0.04	-0.87	-0.91	0.84
Total Operating Expenses	-0.91	0.55	0.09	0.99	1.0	-0.96	-0.92	1.0	-0.91		-0.91	-0.68	-0.91	-0.05	0.93	0.68	-0.54
Income Before Tax	1.0	-0.73	-0.13	-0.92	-0.91	0.98	1.0	-0.9	1.0	-0.91		0.9	1.0	0.02	-0.87	-0.9	0.84
Total Other Income Expense Net	0.9	-0.8	-0.14	-0.73	-0.68	0.8	0.89	-0.65	0.9	-0.68	0.9		0.9	0.0	-0.61	-1.0	0.93
Net Income	1.0	-0.72	-0.13	-0.92	-0.91	0.98	1.0	-0.9	1.0	-0.91	1.0	0.9		0.01	-0.86	-0.9	0.84
Income Tax Expense	0.03	-0.59	0.14	-0.11	-0.05	0.03	0.02	-0.02	0.04	-0.05	0.02	0.0	0.01		-0.32	-0.07	0.03
Gross Profit	-0.87	0.68	0.1	0.92	0.93	-0.93	-0.88	0.93	-0.87	0.93	-0.87	-0.61	-0.86	-0.32		0.64	-0.58
Cost Of Revenue	-0.9	0.84	0.14	0.72	0.68	-0.81	-0.89	0.65	-0.91	0.68	-0.9	-1.0	-0.9	-0.07	0.64		-0.95
Selling And Marketing Expenses	0.83	-0.8	-0.14	-0.57	-0.54	0.74	0.82	-0.52	0.84	-0.54	0.84	0.93	0.84	0.03	-0.58	-0.95

Click cells to compare fundamentals

Unicycive Therapeutics Account Relationship Matchups

Unicycive Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	139K	244K	628K	6K	82K	77.9K
Ebit	(2.0M)	(2.0M)	(9.0M)	(18.1M)	(30.5M)	(28.9M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Unicycive Historical Income Statement

About Unicycive Income Statement Analysis

Unicycive Therapeutics Income Statement Chart

Interest Expense

Total Operating Expenses

Cost Of Revenue

Unicycive Therapeutics income statement Correlations

Unicycive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unicycive Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Unicycive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Ebit
Net Income Applicable To Common Shares	Net Interest Income
Depreciation And Amortization	Selling General Administrative
Total Revenue	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Research Development	Ebitda
Total Operating Expenses	Income Before Tax
Total Other Income Expense Net	Net Income
Income Tax Expense	Reconciled Depreciation
Gross Profit	Cost Of Revenue
Interest Income	Selling And Marketing Expenses

Net Income From Continuing Ops	+ 1.0	Ebit
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses

Cost Of Revenue	- 1.0	Total Other Income Expense Net
Total Operating Expenses	- 0.96	Operating Income
Research Development	- 0.96	Operating Income
Operating Income	- 0.96	Other Operating Expenses
Selling And Marketing Expenses	- 0.95	Cost Of Revenue
Operating Income	- 0.95	Selling General Administrative